{
  "docId": "019de070-f16a-77fb-9c90-c741a7f6a0f0",
  "docSlug": "5e172cf8223e03a5f49c2e34f7f0a14c",
  "documentTitle": "Valneva | IPO Presentation Deck | 41 slides",
  "authorId": "valneva",
  "authorName": "Valneva",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4117647,
  "pageNumber": 3,
  "pageCount": 41,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "use_of_funds",
  "function": "state_next_steps",
  "density": "balanced",
  "nDataPoints": 8,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-f16a-77fb-9c90-c741a7f6a0f0/3",
  "deckHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0",
  "deckJsonHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0.json",
  "deckAnchorHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.57,
        "x": 0.37,
        "y": 0.41
      },
      "kind": "list",
      "text": "Approximately $100 million to fund further development of our Lyme VLA15 vaccine candidate through completion of Phase 2 clinical trials; Approximately $120 million to fund further development of our chikungunya VLA1553 vaccine candidate through BLA approval; Approximately $80 million to fund further development of our COVID-19 VLA2001 vaccine candidate through conditional licensure; and Any remaining amounts to fund working capital and general corporate purposes.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "995e2350-1ff2-4366-aa25-75904c769e5a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.78,
        "w": 0.88,
        "x": 0.06,
        "y": 0.11
      },
      "kind": "table",
      "text": "Issuer: Valneva SE; Ticker: Nasdaq Global Market / VALN; Base Offering Size: 7,082,762 shares / 3,541,381 ADSs; Options: 1,062,414 shares / 531,207 ADSs; ADS ratio: 2:1; Price Range: VWAP based; Use of Proceeds: R&D funding; Cash: €204.4M",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb74ce87-0e5f-43ed-b226-43250c477c5d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.25,
        "x": 0.06,
        "y": 0.06
      },
      "kind": "title",
      "text": "Offering Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a053c2f-c8f4-4b8b-86df-7099b276b219",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}